Longevity Clinics vs Lab Memberships vs Rx Telehealth: What Each Delivers

"Longevity provider" is not one thing. Walk the market and you find a $20,000-a-year concierge clinic with a whole-body MRI scanner, a $149-a-month telehealth membership that mails you a lab kit, a $199-a-year subscription that tests 100 biomarkers and then hands you off, and a pay-per-vial peptide pharmacy — all calling themselves "longevity." They are not substitutes for one another. They deliver fundamentally different things, at prices that differ by two orders of magnitude.

This guide sorts the field into the four bands we use to grade every provider on our longevity rankings, explains what each band actually gives you, and is honest about where each one falls short. The single most useful distinction to carry through: does this provider test, or does it treat? That one question reorganizes the whole market.

The four bands at a glance

| Band | Price (2026) | What you get | The catch | |---|---|---|---| | Concierge diagnostic clinics | $8,000–$25,000/yr | Imaging, genomics, MD concierge | Aspirational pricing; can over-screen | | Membership longevity programs | $99–$300/mo | Recurring labs + clinician + therapies | "Healthspan" claims, supplement upsells | | DTC lab memberships | $199–$365/yr | 100–160+ biomarkers, biological age | They test but largely don't treat | | Single-product Rx telehealth | $99–$235/mo (or pay-per-use) | Peptides, TRT, rapamycin, NAD as discrete Rx | One lane, off-label longevity framing |

The bands overlap at the edges, and a few providers straddle two. But knowing which band you're shopping in tells you most of what you need before you read a single sales page.

Band 1 — Concierge diagnostic clinics ($8k–$25k/yr)

This is the premium ceiling: Fountain Life, Human Longevity (Health Nucleus), Cenegenics, Extension Health. What you're paying for is diagnostics you can't get elsewhere — whole-body and brain MRI, coronary CT angiography with AI plaque analysis, whole-genome sequencing, 100+ biomarker panels, and a physician who quarterbacks all of it. Fountain Life's entry tier runs about $2,995/yr and its flagship around $19,500/yr; Human Longevity's concierge programs reach roughly $19,000/yr; Cenegenics programs land around $14,000–$21,000/yr once you add the assessment and monthly fees.

What it delivers: the deepest picture of your body available to a consumer, MD-interpreted, in person. For some people that catches something genuinely important early.

The honest catch: intensive screening of asymptomatic people is a double-edged sword. The most-cited critique of this model — leveled at whole-body-MRI longevity screening — is that it generates incidental findings that drive anxiety, follow-up procedures, and cost without clearly improving outcomes. The price also puts it out of reach for almost everyone, and "early detection" framing can shade into selling tests to the worried-well. Extension Health adds a second flag: alongside its diagnostics it offers plasma exchange and EBOO as longevity interventions, neither of which has human lifespan-extension evidence behind it. Treat the imaging as the real product and the "reverse aging" interventions as unproven.

Band 2 — Membership longevity programs ($99–$300/mo)

This is the most crowded and most competitive band: Lifeforce, Next Health, Healthspan, Ways2Well, and where CoreAge Rx sits. The model is recurring: a structured panel of 40–100 biomarkers, scheduled retesting every few months, a clinician who reviews results and prescribes, and a menu of therapies — hormone optimization, peptides, GLP-1s, NAD+. Lifeforce runs about $129–$149/mo after a starter diagnostic, and is the band's clearest test-into-treat example — we grade it in our Lifeforce review; Next Health tiers from roughly $99 to $399/mo; Ways2Well's bloodwork membership is around $599/yr with therapies billed separately.

What it delivers: the thing DTC labs don't — it actually treats. You get a clinician who can prescribe and a retesting cadence that lets you see whether an intervention moved your numbers.

The honest catch: this band leans hardest on the word "healthspan," and much of what it prescribes (NAD+, peptides, rapamycin) has mechanistic plausibility but no human longevity RCT. Several brands also run vertical pharmacies — Ways2Well dispenses through its own ReviveRx — which means the same company that recommends a therapy profits from selling it. And the celebrity- or influencer-anchored brands (Lifeforce via Tony Robbins, Marek via a YouTube personality) tend to upsell a house line of nutraceuticals. A good membership provider in this band distinguishes proven from plausible and discloses its conflicts; we grade exactly that in are longevity clinics worth it?.

Band 3 — DTC lab memberships ($199–$365/yr)

Function Health, Superpower, and Tally Health define this band. For a flat annual fee you get a large biomarker panel — Function tests 160+ markers across two draws for $365/yr; Superpower runs 100+ for $199/yr; Tally focuses on at-home epigenetic "biological age" testing — plus a biological-age readout and, usually, a physician who reviews abnormal results. Before you're dazzled by the marker count, it's worth knowing which of those numbers are actually outcome-validated and which are vanity — we sort exactly that in what do longevity biomarker panels actually test?.

What it delivers: an enormous amount of data, cheaply, with minimal friction. As a once-a-year "what's going on inside me" snapshot, it's genuinely useful and well-priced.

The honest catch — the defining one for this band: these providers test but largely don't treat. Function and Superpower will flag an out-of-range marker and may have a physician text you, but they are not built to manage hormone therapy, prescribe peptides, or run a longitudinal treatment plan (we grade the most prominent of these in our Function Health review). You get the diagnosis and then you're handed off to find care elsewhere. Two more caveats: biological-age outputs vary substantially by which method or "clock" is used, so treat the single headline number with skepticism — we explain why the same sample can swing by years in biological age tests: do epigenetic clocks actually work?; and the biological-age science itself is young — the field still lacks the validated, completed human-healthspan trials that would tell you a lower clock score means a longer life¹. Tally's marketing claim that its supplement-and-testing subscription "lowered epigenetic age" is a self-reported figure, not an outcome trial. This is the band where the gap between "raises a lab value" and "improves your health" is widest.

Band 4 — Single-product Rx telehealth ($99–$235/mo or pay-per-use)

Marek Health, AgelessRx, and Hone Health anchor this band. The model is discrete prescriptions: rapamycin, NAD+ injections, sermorelin, compounded GLP-1, or TRT, ordered à la carte or on a per-product subscription. AgelessRx lists NAD+ injections around $235/mo, sermorelin around $99/mo, compounded semaglutide around $139/mo; Hone runs hormone-focused tiers from about $135–$155/mo; Marek is largely pay-per-use after a $250 intake, and we walk through what an intake deposit plus service-by-service billing actually adds up to in its own review.

What it delivers: fast, focused access to a specific therapy without a $20k concierge wrapper. If you know what you want and want it cheaply, this band is efficient. A few members of it borrow from Band 2 and fold the lab work into the subscription rather than billing it as a gate, which narrows the practical gap between the two bands more than the price tags suggest.

The honest catch: these are single lanes, not longevity programs — Hone is really a TRT/hormone service, Marek a hormone-optimization service, regardless of the "longevity" marketing. Several flagship products rest on animal-only or mechanistic evidence: rapamycin is the most reproducible lifespan extender in mice but has no completed human longevity RCT, and NAD+ injections raise a lab value with thin outcome data. AgelessRx leans on compounded medications and cites its own studies — useful, but not a substitute for independent trials. And the vertical-pharmacy conflict reappears: when the prescriber is also the pharmacy, the incentive to prescribe is structural. Read any "anti-aging" claim attached to these products as off-label and mechanistic until proven otherwise; we trace one of the clearest examples in rapamycin for longevity: hype vs evidence.

Where the evidence actually stands across all four bands

It's worth stating plainly, because the marketing across every band blurs it: no longevity intervention sold in any of these bands has been shown in a completed randomized trial to extend human lifespan. The strongest human outcome data in the entire field belongs to GLP-1 receptor agonists — the SELECT trial showed semaglutide cut major cardiovascular events by about 20% in overweight and obese adults without diabetes² — and even that proves cardiovascular risk reduction, not slowed aging (we lay out the full GLP-1 evidence in GLP-1s for healthspan & longevity). Growth hormone, marketed as rejuvenation across several Band 2 and Band 4 providers, runs the other way: a landmark systematic review found it produced small body-composition changes but no proven functional benefit and significantly more adverse events in healthy older adults³. And the IV "longevity" drips that show up on concierge and membership menus alike sit on the weakest evidence of all — a critical review found the data come mostly from disease-specific or aesthetic contexts, with validated aging biomarkers rarely even measured⁴. The honest baseline is shared: the methodology to run true human healthspan trials is only now maturing¹, so every band is operating ahead of the proof. For the full evidence map, see longevity medicine: what's proven vs hyped.

Which band is for you?

• •You want the deepest diagnostic picture and money is no object: Band 1 concierge. Pay for the imaging and genomics; be skeptical of the bolt-on "reverse aging" interventions and the over-screening risk.
• •You want ongoing, prescribed care with retesting and a clinician: Band 2 membership. This is the band that actually treats at an accessible price — vet for conflict-of-interest (vertical pharmacy) and for honesty about what's proven. If you're weighing the premium-imaging ceiling against this accessible-treatment band, we compare them head-to-head in concierge vs membership longevity: what you actually get.
• •You want a cheap, comprehensive annual data snapshot and will arrange care yourself: Band 3 DTC labs. Excellent value for testing; just understand you'll be handed off when something needs treating.
• •You know the one therapy you want and want it efficiently: Band 4 single-product Rx. Efficient and focused — read the longevity claims as off-label, and watch the prescriber-is-the-pharmacy incentive.

The practical reason the bands blur is that the most useful real-world setup often combines them: a Band 3 lab panel for breadth, plus a Band 2 membership or Band 4 Rx for the treatment a DTC lab won't provide. What you should never do is pay Band 1 prices for Band 4 evidence. For our independently graded shortlist across all four bands — with the conflicts and unproven claims flagged — see our longevity provider rankings.